MCAM and neoplasm: In 2006, Aldovini et al. reported that epithelial ovarian cancer patients with high expression of MCAM in tumour tissues had a significantly higher relapse rate than MCAM expression-negative patients and that the survival period of the former group was significantly shorter [12].